

![]() |
Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium |
|
Authors | ![]() | |
Collaboration | ||
Published in | Clinical pharmacology and therapeutics. 2020, vol. 108, no. 5, p. 1067-1077 | |
Abstract | Antiplatelet response to clopidogrel shows wide variation, and poor response is correlated with adverse clinical outcomes. CYP2C19 loss-of-function alleles play an important role in this response, but account for only a small proportion of variability in response to clopidogrel. An aim of the International Clopidogrel Pharmacogenomics Consortium (ICPC) is to identify other genetic determinants of clopidogrel pharmacodynamics and clinical response. A genomewide association study (GWAS) was performed using DNA from 2,750 European ancestry individuals, using adenosine diphosphate-induced platelet reactivity and major cardiovascular and cerebrovascular events as outcome parameters. GWAS for platelet reactivity revealed a strong signal for CYP2C19*2 (P value = 1.67e-33). After correction for CYP2C19*2 no other single-nucleotide polymorphism reached genomewide significance. GWAS for a combined clinical end point of cardiovascular death, myocardial infarction, or stroke (5.0% event rate), or a combined end point of cardiovascular death or myocardial infarction (4.7% event rate) showed no significant results, although in coronary artery disease, percutaneous coronary intervention, and acute coronary syndrome subgroups, mutations in SCOS5P1, CDC42BPA, and CTRAC1 showed genomewide significance (lowest P values: 1.07e-09, 4.53e-08, and 2.60e-10, respectively). CYP2C19*2 is the strongest genetic determinant of on-clopidogrel platelet reactivity. We identified three novel associations in clinical outcome subgroups, suggestive for each of these outcomes. | |
Keywords | Aged — Blood Platelets/drug effects/metabolism — Cardiovascular Diseases/blood/genetics/mortality/prevention & control — Clopidogrel/adverse effects/therapeutic use — Coronary Artery Disease/mortality/therapy — Cytochrome P-450 CYP2C19/genetics/metabolism — Female — Genome-Wide Association Study — Humans — Male — Middle Aged — Percutaneous Coronary Intervention/adverse effects/mortality — Pharmacogenetics — Pharmacogenomic Variants — Platelet Aggregation Inhibitors/adverse effects/therapeutic use — Polymorphism, Single Nucleotide — Risk Assessment — Risk Factors — Treatment Outcome | |
Identifiers | DOI: 10.1002/cpt.1911 PMID: 32472697 | |
Full text | ||
Structures | ||
Research group | Geneva Platelet Group (13) | |
Citation (ISO format) | VERMA, Shefali Setia et al. Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. In: Clinical Pharmacology and Therapeutics, 2020, vol. 108, n° 5, p. 1067-1077. doi: 10.1002/cpt.1911 https://archive-ouverte.unige.ch/unige:155381 |